Ushering a New Era in the Management of Hepatitis C in Children with Hematological Disorders
Transfusion-transmitted hepatitis C is a major concern among thalassemia patients. Our aim is to estimate the prevalence of Hepatitis C infection among thalassemia patients and to assess the treatment response, adverse effects of Peg-interferon based regimen and the new direct-acting antiviral drugs. Patients with thalassemia receiving regular blood transfusions with positive anti HCV antibodies during a period from January 2012 to June 2017 were analyzed. Serial HCV viral load and genotype and liver function tests were performed. Peg interferon and Ribavirin were used in patients diagnosed before January 2016 and patients diagnosed after January 2016 were started on the combination of Ledipasvir/Sofosbuvir. Thirty-two patients aged between 2 and 28 years were analyzed. Genotype 1 was the predominant type. Twenty-one patients were initiated on Peg Interferon with Ribavirin, and 14 achieved sustained virological response. All of them had increased blood transfusion requirements with significant compliance issues. All eleven patients started on Ledipasvir and Sofosbuvir including 4 undergoing hematopoietic stem cell transplantation and 7 interferon failures showed sustained viral clearance with good compliance. Ledipasvir/Sofosbuvir combination can be safely used in thalassemia patients and in young children. The cost of therapy is less compared to peg interferon based regimen with good compliance and superior efficacy.
KeywordsHepatitis C Interferon Ledipasvir and Sofosbuvir Sustained viral response
Hepatitis C virus
American Association for the Study of the Liver Disease
European Association for the Study of the Liver
Direct acting anti virals
Sustained virological responcse
Compliance with Ethical Standards
Conflict of interest
All authors agree that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from the all the individual patients included in the study.
- 1.Thalassaemia International Federation (2015) HCV position paper. Viral hepatitis C in thalassaemia, pp 14–15Google Scholar
- 3.Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P, Kattamis A, Prossamariti L, Filosa A, Rund D, Gamberini MR (2010) Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood 116(16):2875–2883CrossRefPubMedGoogle Scholar
- 4.Craxi A, Pawlotsky J, Wedemeyer H, Bjoro K, Flisiak R, Forns X, Mondelli M, Peck Radosavljevic M, Rosenberg W, Sarrazin C, Jacobson I (2011) European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 55(2):245–264CrossRefGoogle Scholar
- 6.Food US (2014) Drug Administration approves Gilead’s Harvoni (ledipasvir/sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C. [internet]. Foster City (CA): Gilead Sciences, Inc, p 4. Accessed 25 Nov 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm
- 7.Release FN (2017) FDA approves two hepatitis C drugs for pediatric patients. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm